These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26212869)

  • 1. Ibrutinib promising in subtype of DLBCL.
    Brower V
    Lancet Oncol; 2015 Sep; 16(9):e428. PubMed ID: 26212869
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of ibrutinib in the treatment of Richter syndrome.
    Tsang M; Shanafelt TD; Call TG; Ding W; Chanan-Khan A; Leis JF; Nowakowski GS; Bowen D; Conte M; Schwager SM; Slager SL; Kay NE; Hanson CA; Parikh SA
    Blood; 2015 Mar; 125(10):1676-8. PubMed ID: 25745187
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
    Wiestner A
    J Clin Oncol; 2013 Jan; 31(1):128-30. PubMed ID: 23045586
    [No Abstract]   [Full Text] [Related]  

  • 4. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
    Zhang L; Newberry KJ; Wang M
    Expert Rev Clin Immunol; 2013 Jun; 9(6):495-7. PubMed ID: 23730878
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib approved for mantle cell lymphoma.
    Cancer Discov; 2014 Jan; 4(1):OF1. PubMed ID: 24402946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
    Leong DP; Caron F; Hillis C; Duan A; Healey JS; Fraser G; Siegal D
    Blood; 2016 Jul; 128(1):138-40. PubMed ID: 27247135
    [No Abstract]   [Full Text] [Related]  

  • 8. Toward new treatments for mantle-cell lymphoma?
    Zucca E; Bertoni F
    N Engl J Med; 2013 Aug; 369(6):571-2. PubMed ID: 23924008
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
    Christoforidou A; Kapsas G; Bezirgiannidou Z; Papamichos S; Kotsianidis Ι
    Turk J Haematol; 2018 May; 35(2):147-149. PubMed ID: 29391330
    [No Abstract]   [Full Text] [Related]  

  • 10. A new era of treatment for chronic lymphocytic leukaemia?
    Brown JR
    Lancet Oncol; 2014 Jan; 15(1):3-5. PubMed ID: 24332240
    [No Abstract]   [Full Text] [Related]  

  • 11. Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
    Sun Y; Ding N; Song Y; Yang Z; Liu W; Zhu J; Rao Y
    Leukemia; 2019 Aug; 33(8):2105-2110. PubMed ID: 30858551
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
    Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
    Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib-Induced Lymphocytosis: Cytological Features.
    Quintela A; Sujobert P; Callet-Bauchu E; Salles G; Baseggio L
    Acta Haematol; 2017; 137(1):55-57. PubMed ID: 27960168
    [No Abstract]   [Full Text] [Related]  

  • 14. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
    Wanquet A; Birsen R; Lemal R; Hunault M; Leblond V; Aurran-Schleinitz T
    Blood; 2016 May; 127(19):2356-8. PubMed ID: 26994148
    [No Abstract]   [Full Text] [Related]  

  • 15. [Ibrutinib prescription in B-cell lymphoid neoplasms].
    Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
    Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR
    Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
    Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
    Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.